

**Contact: Hariharan Subramanian**  
AtheroSolve, Inc.  
Phone: (617) 553-1015  
701 Concord Avenue  
Cambridge, MA 02138  
info@atherosolve.com  
www.atherosolve.com



---

# PRESS RELEASE

AtheroSolve, Inc. is incorporated as a Delaware corporation

**Cambridge, February 9, 2017:** AtheroSolve, Inc. is incorporated as a Delaware corporation.

Based on proprietary in silico technology and a feedback systems design that mines existing peer-reviewed literature for validated molecular mechanisms, while reusing scientific data from wet lab and clinical trials, AtheroSolve offers a revolutionary and proven integrative information-centric platform that accurately model complex molecular mechanisms in atherosclerosis. These models enable rapid in silico testing for the development of single and multi-combination compounds for drugs by optimizing in vitro and in vivo testing. AtheroSolve will be headed by Dr. Shiva Ayyadurai as the Chief Executive Officer.

AtheroSolve is headquartered in Cambridge, MA. AtheroSolve uses CytoSolve's revolutionary technology for in silico mechanistic modeling is accelerating discovery and development of single and multi-combination therapeutics for atherosclerosis.